The global acquired hemophilia treatment market size is likely to project a CAGR of 3.6% during the forecast years 2021-2028. Unlike cases of classical hemophilia which is characterized by the deficiency of factor VIII or IX, acquired hemophilia is acknowledged as a rare clinical condition wherein autoantibodies at adulthood is identified that lead to deactivated functionality of factor VIII. These conditions contribute towards inflamed blood vessels, besides forming skin lesions and even purpura which is essentially skin hemorrhages. The ideal therapeutic approach for acquired hemophilia is to arrest persistent bleeding occurrences. This autoimmune disease is characterized to maneuver excessive autoimmune formation against one's self produced proteins which are inappropriately identified as foreign elements.
The present and future acquired hemophilia treatment market progress is summarized to conclude the attractiveness of the entire market. Rising prevalence of acquired hemophilia and surge in geriatric population will drive the acquired hemophilia treatment market during the forecast years. However, the exorbitant cost associated with the bypassing agents employed as hemostatic therapy to control bleeding episodes will hamper the acquired hemophilia treatment market growth.
Adroit Market Research report on global acquired hemophilia treatment market gives a holistic view of the market, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for the period 2019 to 2028, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market based on Porter's five forces analysis and positions the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global acquired hemophilia treatment market have been studied in detail.
Based on therapy, the acquired hemophilia treatment market is categorized into inhibitor eradication therapy, and hemostatic therapy. The hemostatic therapy segment seized the maximum market share in 2020 and it is likely to maintain its place throughout the forecast years. Hemostatic therapy comprises desmopressin and Obizur which are frequently employed to manage minor bleeding complications due to hemorrhage of peripheral blood vessels by increasing the circulating blood plasma levels of clotting factor VIII in the human body, whereas, NovoSeven RT and FEIBA are used to manage major bleeding complications in hemorrhage of vital internal organs.
North America is anticipated to hold majority market share in the global acquired hemophilia treatment market in 2020. Increasing prevalence of acquired hemophilia in the U.S. is a major factor for its dominance. According to the Center for Disease Control and Prevention (CDC), the prevalence rate of acquired hemophilia in the United States is 0.2 to 1 per million people. However, Asia Pacific is expected to outpace other regions growing with a CAGR of 4.3% during the forecast period on account of the rising prevalence of acquired hemophilia in elderly population and existence of lucrative business opportunity for western giants to establish subsidiaries in the region. Moreover, FastTrack status awarded by local healthcare authorities for the drug development pertaining to rare and orphan disease in Asia Pacific is expected to drive the acquired hemophilia treatment market growth.
The major players of the global acquired hemophilia treatment market are Baxter Healthcare Corporation, BioXcel Corporation, Genentech, Inc., GlaxoSmithkline, Plc., Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. and Teva Pharmaceutical Industries Ltd.
Key Segments of the Global Acquired Hemophilia Treatment Market
Therapy Overview, 2019-2028 (USD Million)
- Inhibitor Eradication Therapy
- Cytotoxic Agents
- Immunomodulatory Agents
- Hemostatic Therapy
- Recombinant Activated Factor VII/NovoSeven RT
- Recombinant Activated Factor VIII/Obizur
- Activated Prothrombin Complex Concentrate (aPCC)/FEIBA
Regional Overview, 2019-2028 (USD Million)
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and Africa
- Rest of Middle East and Africa